Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEPHAISTOS: Everolimus with Reduced Tacrolimus in Liver Transplant
NCT01551212Phase 4Completed
- Sponsor
- Novartis
- Start
- May 2012
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of everolimus in Liver transplant rejection (2 arms), sponsored by Novartis. Primary endpoint: Estimated Glomerular Filtration Rate at 12 months. Started May 2012; status: completed.
02
Drugs
everolimus
03
Conditions
Liver transplant rejection
Beyond the preview
Go deeper on NCT01551212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01551212.